BIOCRYST PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.21 USD | -3.88% |
|
-8.08% | -29.72% |
Presentation Operator MessageOperator (Operator)Welcome to the BioCryst Second Quarter 2022 Ea...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Calendar
2024-05-06
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
4.21
USD
Average target price
12.2
USD
Spread / Average Target
+189.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.72% | 903M | |
| -1.51% | 105B | |
| +3.22% | 97.5B | |
| +1.86% | 22.19B | |
| -16.53% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.09% | 14.52B | |
| +5.47% | 14.09B | |
| +28.85% | 10.99B |
- Stock Market
- Equities
- BCRX Stock
- News BioCryst Pharmaceuticals, Inc.
- Transcript : BioCryst Pharmaceuticals, Inc., Q2 2022 Earnings Call, Aug 04, 2022
